CD4 and coinfection: In contrast to previous systematic review findings (6, 14, 15, 52, 55) and primary studies (6, 7, 14, 15, 30, 37, 40, 42, 43, 52, 55), this meta-regression found no significant association between declined CD4 count (≤200 cells/mL), age of patients, duration of follow-up, comorbidity status, and body mass index with the risk of death during TB and HIV co-infection treatment (AHR = 2.18, 95% CI: 0.97–3.08, I2 = 82.8%, p = 0.064).